estazolam

Trade name: prosom

Small moleculeapproved

Approved

Dec 26, 1990

Estazolam, a triazolobenzodiazepine derivative, is an oral hypnotic agent with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Used for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Marketed under the brand names ProSom, Eurodin. — NCATS

Clinical trial activity

4 trials · 4 clinical orgs · 6 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
2

Earliest trial started Jun 1, 2006 (NCT00347295)

Timeline

1990s

  1. Dec 26, 1990

    Abbott — Earliest FDA Approval

  2. Dec 26, 1990

    Abbott — NDA Organization

  3. Jul 3, 1997

    Par Pharmaceuticals — Marketing Organization

  4. Jul 3, 1997

    Novitium Pharma — Marketing Organization

  5. Jul 10, 1997

    Mayne Pharma — Marketing Organization

  6. Jul 10, 1997

    Dr. Reddy's Laboratories — Marketing Organization

  7. Aug 19, 1997

    Watson Pharmaceuticals — Marketing Organization

2000s

  1. Jan 1, 2006

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedDec 26, 1990

Chemistry & pharmacology

Loading structure…

SMILES

ClC1=CC=C2N3C=NN=C3CN=C(C4=CC=CC=C4)C2=C1
Mol. weight
294.738 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • 8-chloro-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine
  • 8-chloro-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine
  • abbott-47631
  • abbott-47631
  • estazolam
  • estazolam
  • estazolam
  • estazolam
  • estazolam
  • estazolam
  • estazolam
  • estazolam
  • estazolam
  • estazolam
  • estazolamum
  • estazolamum
  • eurodin
  • eurodin
  • prosom
  • prosom
  • prosom
  • tasedan

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05452577N/AJan 22, 2021Nanjing Medical University
NCT03997058Phase 4Jun 1, 2019Guangzhou University
NCT00956319Phase 4May 1, 2009Astellas
NCT00347295Phase 3Jun 1, 2006Boehringer Ingelheim
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstellasFor profit1112009
Boehringer IngelheimFor profit1112006
Guangzhou UniversityAcademic/Hospital1112019
Nanjing Medical UniversityAcademic/Hospital1112021
4 organizations
Page 1 / 1

Marketing (6)

OrganizationOrg typeRelationshipDate
AbbottFor profitNDADec 26, 1990
Dr. Reddy's LaboratoriesFor profitMKTGJul 10, 1997
Mayne PharmaFor profitMKTGJul 10, 1997
Novitium PharmaFor profitMKTGJul 3, 1997
Par PharmaceuticalsFor profitMKTGJul 3, 1997
Watson PharmaceuticalsFor profitMKTGAug 19, 1997